Serum histamine and acetylcholine variations as new noninvasive biochemical markers in staging of experimental hepatocellular carcinoma
Angiogenesis is a major prerequisite for hepatocellular carcinoma (HCC) development and progression. The present study aims to assess the potential role of two endogenous regulators of angiogenesis histamine (His) and acetylcholine (Ach), as possible biochemical markers for staging of HCC. Five groups of rats were used in this study: a control healthy group (I), another 4 intoxicated groups used for the induction of HCC with a high dose of diethyl nitrosamine (DENA, 200 mg/kg, single I.P. dose), (II, III, IV, and V). Groups II, III, IV, and V were killed following 8, 16, 24, and 32 weeks after DENA injection, respectively. Serum level of His and Ach was estimated using high-performance liquid chromatography technique coupled with diode array detector (HPLC–DAD), and alpha-fetoprotein (AFP) was measured using ELISA technique along with liver histological examination for all groups. Progression of HCC was estimated by histopathological examination. The results exhibited prominent increase in serum His and Ach levels during the early stages of HCC in group II, III in comparison with the control, and then His serum level declined to the normal level during the last stage of HCC development (group V).However, Ach elevation continued. AFP serum level showed marked increase, till 32 weeks after hepatocarcinogenesis. The decreased histamine level, combined to elevated AFP, indicates an early stage, while continued elevation of Ach with decreased His levels indicates a later stage of HCC. The combination of these two neurotransmitters to AFP may contribute to a noninvasive biochemical staging for HCC.
KeywordsHepatocellular carcinoma Histamine Acetylcholine AFP Staging
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
All the animal experiments were conducted in accordance with the guide for the care and use of laboratory animals of the Faculty of Pharmacy, Kafrelsheikh University, Egypt.
The experiment is not a clinical study, so not applicable.
- 7.Freedman LS, Edwards B, Ries L, Young J. Cancer incidence in four member countries (Cyprus, Egypt, Israel, and Jordan) of the Middle East Cancer Consortium (MECC) compared with US SEER. Cancer incidence in four member countries (Cyprus, Egypt, Israel, and Jordan) of the Middle East Cancer Consortium (MECC) compared with US SEER, 2006.Google Scholar
- 8.Ibrahim AS, Khaled HM, Mikhail NN, Baraka H, Kamel H. Cancer incidence in Egypt: results of the national population-based cancer registry program. J Cancer Epidemiol. 2014;2014.Google Scholar
- 9.Tanaka Y, Hanada K, Mizokami M, et al. A comparison of the molecular clock of hepatitis C virus in the United States and Japan predicts that hepatocellular carcinoma incidence in the United States will increase over the next two decades. Proc Natl Acad Sci. 2002;99(24):15584–9.PubMedCrossRefGoogle Scholar
- 10.Abdel-Hamid M. Priority considerations in early laboratory diagnosis of hepatocellular carcinoma. IJIB. 2008;3(3):196–201.Google Scholar
- 25.Pós Z, Hegyesi H, Rivera ES. Histamine and cell proliferation. Histamine: biology and medical aspects. 1st ed. Budapest: SpringMed Publishing Ltd; 2004. p. 199–217.Google Scholar
- 47.Cervello M, Foderà D, Florena AM, et al. Correlation between expression of cyclooxygenase-2 and the presence of inflammatory cells in human primary hepatocellular carcinoma: possible role in tumor promotion and angiogenesis. World J Gastroenterol. 2005;11(30):4638.PubMedPubMedCentralCrossRefGoogle Scholar